Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAP-1002 in severe COVID-19
NCT04623671Phase 2Completed
- Sponsor
- Capricor Therapeutics
- Start
- Nov 2020
- Primary completion
- Feb 2022
- Modality
- Mesenchymal Stem Cells, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of deramiocel in coronavirus disease 2019 (COVID-19), sponsored by Capricor Therapeutics. Started Nov 2020; status: completed.
02
Drugs
deramiocel
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04623671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623671.